Results 141 to 150 of about 154,569 (253)
T cells, the Next Big Target in Axial Spondyloarthritis?
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
Thoracic Imaging Findings in Systemic Lupus Erythematosus. [PDF]
Kendyala S, Kapoor A, N R.
europepmc +1 more source
Objective Hydroxychloroquine (HCQ) nonadherence in systemic lupus erythematosus (SLE) stemming from decision complexities can be improved with shared decision‐making (SDM) tools clarifying benefits and harms. This study aimed to develop and evaluate HCQ‐SAFE, a pictogram‐based SDM tool during SLE visits.
Caroline Packee +8 more
wiley +1 more source
Plasmacytoid dendritic cells in systemic and cutaneous lupus erythematosus: an evolving understanding. [PDF]
Werth VP +8 more
europepmc +1 more source
Objective The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM2.5) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset.
Naizhuo Zhao +9 more
wiley +1 more source
Clinical, imaging characteristics, and outcomes of neuropsychiatric lupus patient admitted to a referral neurology hospital in Bangladesh: A prospective study. [PDF]
Been Sayeed SKJ +5 more
europepmc +1 more source
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia +16 more
wiley +1 more source
Clinical predictors for bloodstream infection in systemic lupus erythematosus. [PDF]
Ye M +6 more
europepmc +1 more source
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun +4 more
wiley +1 more source
Anti-CD19 monoclonal antibody for systemic lupus erythematosus and neuromyelitis optica spectrum disorder. [PDF]
Gonzalez Manrique P +3 more
europepmc +1 more source

